Monopar Therapeutics (MNPR) Institutional Ownership $42.96 +0.25 (+0.59%) Closing price 04:00 PM EasternExtended Trading$42.84 -0.12 (-0.28%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Monopar Therapeutics (NASDAQ:MNPR)CurrentInstitutional OwnershipPercentage1.83%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$54.60MNumber ofInstitutional Sellers(last 12 months)0 Get MNPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Monopar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MNPR Institutional Buying and Selling by Quarter Monopar Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Point72 Asset Management L.P.167,892$3.69M0.0%N/A2.752% 2/17/2025Janus Henderson Group PLC1,046,899$23.44M0.0%N/A17.162% 2/14/2025RA Capital Management L.P.511,207$11.25M0.1%N/A8.380% 2/14/2025Adage Capital Partners GP L.L.C.599,195$13.18M0.0%N/A9.823% 2/13/2025ADAR1 Capital Management LLC130,037$2.86M0.6%N/A2.132% 2/12/2025Geode Capital Management LLC38,596$849K0.0%+174.4%0.633% 2/12/2025JPMorgan Chase & Co.2,037$45K0.0%N/A0.033% 10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635% 8/13/2021Geode Capital Management LLC28,761$169K0.0%+9.0%0.229% 8/13/2021Vanguard Group Inc.97,462$574K0.0%+116.2%0.775% 5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073% 5/12/2021Northern Trust Corp36,001$223K0.0%-38.8%0.286% 5/12/2021Geode Capital Management LLC26,394$163K0.0%N/A0.210% 5/7/2021BlackRock Inc.11,229$70K0.0%+108.3%0.089% 2/11/2021Northern Trust Corp58,793$360K0.0%-9.2%0.513% (Data available from 1/1/2016 forward) MNPR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MNPR shares? During the previous two years, the following institutional investors and hedge funds held shares of Monopar Therapeutics shares: Janus Henderson Group PLC ($23.44M), Adage Capital Partners GP L.L.C. ($13.18M), RA Capital Management L.P. ($11.25M), Point72 Asset Management L.P. ($3.69M), ADAR1 Capital Management LLC ($2.86M), Geode Capital Management LLC ($849K), and Windsor Advisory Group LLC ($56K).Learn more on MNPR's institutional investors. What percentage of Monopar Therapeutics stock is owned by institutional investors? 1.83% of Monopar Therapeutics stock is owned by institutional investors. Learn more on MNPR's institutional investor holdings. Which institutional investors have been buying Monopar Therapeutics stock? The following institutional investors have purchased Monopar Therapeutics stock in the last 24 months: Janus Henderson Group PLC ($1.05M), Adage Capital Partners GP L.L.C. ($599.20K), RA Capital Management L.P. ($511.21K), Point72 Asset Management L.P. ($167.89K), ADAR1 Capital Management LLC ($130.04K), Windsor Advisory Group LLC ($89.97K), and Geode Capital Management LLC ($24.53K). How much institutional buying is happening at Monopar Therapeutics? Institutional investors have bought a total of 2,571,771 shares in the last 24 months. This purchase volume represents approximately $54.88M in transactions. Related Companies Mineralys Therapeutics Major Shareholders 89bio Major Shareholders Collegium Pharmaceutical Major Shareholders Dyne Therapeutics Major Shareholders Enliven Therapeutics Major Shareholders Arcus Biosciences Major Shareholders Chimerix Major Shareholders Avid Bioservices Major Shareholders Spyre Therapeutics Major Shareholders Intellia Therapeutics Major Shareholders This page (NASDAQ:MNPR) was last updated on 4/22/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrade War Just Turned 3 Unknown Stocks Into Rocket FuelThe Real Catalyst Behind America’s Next Bull Run One overlooked sector is being completely repriced — and s...Insiders Exposed | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
